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A b s t r a c t  
Metformin is a hydrophilic hypoglycemic agent with permeability and short half-life problems which 
leads to its low bioavailability. Solid dispersion is one of the unique approaches, to improve 
bioavailability profiles of drugs. The aim of this study was to prepare and evaluate solid dispersions 
(SDs) of metformin with polyethylene glycol 4000 (PEG 4000) and Gelucire®50/13 in order to 
increase its permeability and bioavailability. Solid dispersions of Metformin containing various ratios 
of PEG 4000: Gelucire®50/13 (1:1, 1:2, 2:1, 1:4, 4:1 as Batch A, Batch B, Batch C, Batch D and 
Batch E) was prepared using solvent evaporation and fusion techniques. The physical mixtures 
which served as controls were also prepared. The SDs was evaluated using encapsulation 
efficiency, percentage yield. The formulations were also characterized with FTIR and DSC. The in 
vitro drug release studies were also evaluated. The results obtained showed that solid dispersion 
formulations at pH, 1.2 and 7.4 demonstrated higher release rates than the pure drug. The SDs 
showed high drug release rates and encapsulation efficiency (% EE) although Batch C containing 
PEG 4000 and Gelucire 50/13 in the ratio of 2:1 appeared as the batch with most % EE, drug 
release with broad melting peak. The release rate of metformin increased with increasing amount of 
PEG 4000. Batch C, SDs containing PEG 4000 and Gelucire 50/13 in the ratio of 2:1 were found to 
be the most optimized batch with enhanced encapsulation efficiency, most drug release and 
therefore, improved permeability and bioavailability of metformin. 
Keywords: Solid dispersion, Metformin, Gelucire, bioavailability and characterization. 
Introduction 
 
Metformin is an oral antihyperglycemic agent from biguanide class.  
It is used for the management of patients with noninsulin-dependent 
diabetes mellitus (NIDDM), particularly those with refractory obesity 
[1]. It belongs to class III of biopharmaceutical classification system 
with low permeability property. It is highly water-soluble, whose low 
bioavailability and short and variable biological half-life (1.5–4.5 h) 
needs frequent administrations to maintain effective plasma 
concentrations [2]. It has a relatively low bioavailability (50 – 60%) 
[3,4].   Solid dispersion (SDs) is one of the approaches to increase 
permeability of drug substance. SDs enables reduction of particle 
sizes up to molecular level which will enhance permeability of the 
poorly permeable drugs. Therefore, particle size reduction, leading 
to increased surface area, is a very promising approach to enhance 
permeability rate and, thus, the bioavailability of poorly permeable 
compounds. When the solid dispersion formulation is exposed to 
aqueous media, the drug-carrier dissolves and the drug releases as 
fine colloidal dispersions and the particles having being in a very 
reduce or molecular level during the formulation will be able to 
permeate the membrane without much difficulty. The present study 
was based on the objective of improving the permeability of poorly 
permeable anti-hyperglycemic drug, metformin using solvent 
evaporation and fusion methods of solid dispersion techniques with 
combined ratio of two lipophilic polymers.  
The use of polymeric carriers in enhancing the solubility and 
bioavailability of drugs has increased tremendously. The two 
polymers, PEG and Gelucire have been used in the formulations of 
solid dispersions [5, 6].  
PEG is often used as vehicle because of its low toxicity, low melting 
point, rapid solidification rate, high aqueous solubility, availability in 
various molecular weights, economic cost, and physiological 
tolerance. A particular advantage of PEGs for the formation of SDs 
is that they have good solubility in many organic solvents. The 
melting point of PEG is low in all cases, which is advantageous for 
manufacturing SDs. Additional attractive features of PEGs include 
their ability to solubilize some compounds and improve compound 
wettability. These and other properties make PEG a suitable vehicle 
in the formulation of dosage forms s [7, 5-6, 8-10].  
Gelucire on the other hand, is a member of vehicle deduced from 
the mixture of mono- di- and triglycerides with PEG esters of fatty 
acids. They have numerous uses in pharmaceutical preparations 
such as in formulation of immediate and controlled release drugs 
[11-13].  
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These polymers were selected as carriers in this research work for 
the formulation of solid dispersion of a hydrophilic drug, Metformin, 
for two distinct reasons:  to equip and improve the poor permeability 
nature of the drug in order to cross the cell membrane without 
difficulty and to improve the short half life of the drug by the 
sustained activity of the carriers.  
 
Material and Methods 
 
Materials 
 
Metformin (Indoco Remedies Goa, India), PEG 4000 (Sisco 
Research laboratories Pvt Ltd), Gelucire®50/13 (Gattefosse, St. 
Priest, France), HCl (Merck, Germany). All other reagents and 
solvents used were of analytical grade.  
 
Methods 
 
Preparation of metformin solid dispersions by solvent 
evaporation method 
 
Metformin solid dispersions were prepared with PEG 4000 and 
Gelucire® 50/13 in various ratios (1:1, 1:2, 2:1, 1: 4, and 4:1 as 
Batch A, Batch B, Batch C, Batch D and Batch E respectively) using 
solvent evaporation and fusion methods. The amount of metformin 
was constant in all the five (5) batches in all the methods. The 
appropriate weight of the drug and the polymers was weighed out 
as shown in Table 1. Gelucire® 50/13 was dissolved in methylene 
chloride while PEG 4000 was dissolved in methanol (as little 
quantity as can dissolve the polymer were used). Then, both of 
them were mixed together before the drug was introduced and 
stirred vigorously for up to 5 min as the solvent evaporates. It was 
then kept to dry at room temperature for one week.  
 
Preparation of metformin solid dispersions by Melting 
(fusion) method 
 
Solid dispersions were prepared by melting the accurately weighed 
amounts of PEG 4000 and Gelucire® 50/13 (Table. 1) in a water 
bath and the drug was dispersed in the molten solution. The 
mixtures were stirred repeatedly, after 10 min. they were cooled by 
placing the container in an ice bath. Solid mass obtained was 
passed through the No. 80 sieve and stored in air tight container 
until used.  
 
Physical mixtures  
 
The physical mixtures were prepared by using the formula in Table 
1. Then mixed in a mortar by trituration. The resultant mixture was 
passed through No. 80 sieve and stored until used. 
 
Table 1: Table for the formulation of glibenclamide solid dispersions 
Ratio PEG 4000 (mg) Gelucire (mg) Metformin (mg) 
Batch A 200  200  100  
Batch B 200  400  100  
Batch C 400  200  100 
Batch D  200  800  100 
Batch E 800  200  100 
 
Preparation of Beer-Lambert’s plot for metformin 
 
A 10 mg quantity of pure metformin was weighed out into a 
measuring cylinder. A 10 ml of methanol was used to dissolve the 
drug. The solution filtered and the volume was made up to 100 ml 
with phosphate buffer. It was filtered and the filtrate was diluted 
serially to obtain (2 - 12 mg %) concentrations of metformin. The 
absorbance readings of these solutions were taken using UV-
spectrophotometer (Jenway, 6405, UK) at 232 nm. A graph of 
absorbance against concentration was plotted and the slope 
measured. 
 
Determination of Percentage Yield  
  
The percentage yield is useful to determine the efficiency of a 
preparation technique. The percentage yield was calculated by 
using the equation [14]:  
 
          	      =
        	    ℎ   ℎ         	      	  	 ℎ 	    	 × 100⁄  ...1 
 
Determination of encapsulation efficiency 
 
An amount containing 100 mg metformin prepared by different 
methods and the different ratios was weighed out. It was dissolved 
in 10 ml of methanol, filtered and was made up to 100 ml using 
phosphate buffer. Then, a 2-10 fold dilution was prepared with 
phosphate buffer. This was assayed using spectrophotometer 
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(Jenway, 6405, UK) at 232 nm. Their encapsulation efficiency was 
calculated using the formula below: 
 
             	          	(%) =
      	    	       
           	    	       
× 100 
…………..2 
 
In vitro dissolution analysis of metformin solid 
dispersions 
 
The in vitro dissolution analysis was carried out on all the batches of 
metformin solid dispersions and metformin pure drug. This was 
carried out using USP XXII type I dissolution test apparatus with 
dialysis membrane placed in a dissolution medium. A 900 ml of the 
dissolution medium (SIF) at pH, 7.4 was maintained at 37±1oC by 
means of a thermostat set at 100 rpm. The dialysis membrane was 
immersed in the SIF for 20 min, with the aid of an insulin needle; it 
was opened and was then tied at one end with a thread. Then, an 
amount containing 100 mg of metformin was weighed out and 
transferred into the dialysis membrane. The other end of the dialysis 
membrane was then tied and immersed in the dissolution medium. 
A 5 ml aliquot withdrawn from the dissolution medium was made 
and replaced with 5 ml of fresh SIF at different time intervals (30, 
60, 90, 120 … 360 min). They were analyzed for their drug content 
using spectrophotometer (Jenway, 6405, UK) at 232 nm. This was 
performed for all the batches and the procedure repeated using 
simulated gastric fluid (SGF) at pH 1.2 for about 6 h. 
 
Characterization of the solid dispersion formulation 
Differential scanning calorimetric analysis  
Melting transitions and changes in heat capacity of the lipid matrices 
were determined using a calorimeter (Netzsch DSC 204 F1, 
Germany). About 1 mg of each excipient and solid dispersion were 
weighed into an aluminum pan, hermetically sealed and the thermal 
behavior determined in the range of 10-80 °C at a heating rate of 5 
°C/min. The temperature was held at 80 °C for 10 min and 
thereafter, cooled at the rate of 5 to 10 °C/min. Baselines were 
determined using an empty pan, and all the thermograms were 
baseline corrected.  
 
FTIR Spectroscopy  
 
The solid state interactions between the drug and carriers in solid 
dispersions was studied by Infrared spectroscopy. The finely 
powdered pure drug or drug carrier dispersion system was 
intimately mixed with potassium bromide and compressed into 
transparent pellet. I.R. spectra were obtained on a FTIR 
spectrometer (FTIR-640, Varian. Australia) at 4000 to 400cm-1 
[15,16]. 
 
Results and Discussion  
 
Results of the Beer-Lambert’s plot 
 
The Beer-Lambert’s plot which is the plot of absorbance against 
concentrations is shown in Figure 1. The plot gave a linear graph at 
R2 = 0.997.  
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Figure 1: Beer-Lambert's plot for pure metformin 
 
Percentage yield of metformin   
   
The percentage practical yield was found to be high across the 
different batches with different methods. It ranged between 91.3 to 
99.2 % as shown in Table. 2. The maximum percentage practical 
yield was found to be 99.2 % for Batch C. Among the methods 
Physical mix (PM) had the highest yield followed by Solvent 
evaporation (S.E) method and finally the fusion (FM) method. 
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Table 2: Percentage yield of metformin 
Batches  S.E (%)    FM (%)  PM (%)  
Batch A 95.2 93.7 98.3 
Batch B 93.5 90.1 94.7 
Batch C 98.8 95.3 99.2 
Batch D  95.7 91.3 96.5 
Batch E 95.5 93.3 97.7 
 
The encapsulation efficiency  
   
The encapsulation efficiency (% EE) represented in Table. 3 
showed that the encapsulation efficiency increased with increased 
amount of polymers but was more at Batch C. Therefore, Batch C 
has the highest encapsulation efficiency.  
 
Table 3: Table for the encapsulation efficiency 
Batches SE. (M±SD %) FM (M±SD %) PM (M±SD %) 
Batch A 42 ±0.27 42 ±0.95 42 ±0.50 
Batch B 50 ±0.15 51 ±0.76 51 ±0.15 
Batch C 81±0.10 72 ±0.89 74 ±0.66 
Batch D  62±0.74 72 ±0.07 67 ±0.11 
Batch E 53 ±0.66 54 ±0.76 51 ±0.15 
 
Results of the in vitro dissolution studies   
 
The results of in vitro dissolution properties of metformin solid 
dispersion formulations and pure metformin sample were shown in 
Figures 2-7. Comparing the release profiles of the pure samples of 
metformin and the solid dispersions, it was shown that metformin 
solid dispersion formulations gave higher release than the pure 
sample. This might be due to increased permeability of metformin 
as a result of high porosity created by solid dispersion formulations.  
Also Batch C with higher encapsulation efficiency gave the highest 
release in the dissolution studies in both SGF and SIF. The fusion 
melting method gave the highest release followed by solvent 
evaporation method and then, the physical mix.   
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Figure 2: Dissolution of metformin from the solid dispersions prepared by solvent evaporation method in SIF. 
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Figure 3: Dissolution of metformin from the physical mixtures in SIF. 
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Figure 4: Dissolution of metformin from the SDs prepared by fusion method in SIF. 
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Figure 5: Dissolution of metformin from the SDs preparation by physical mixture in SGF. 
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Figure 6: Dissolution of metformin from the SDs preparation by solvent evaporation in SGF. 
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Figure 7: Dissolution of metformin from the SDs preparation by fusion method in SGF. 
 
Thermal properties 
 
The thermograms of the pure metformin exhibited a sharp 
endothermic melting peak at 232.0 oC as shown in figure 9.  While 
figure 9-11 is showing the DSC thermograms of pure PEG 4000 and 
gelucire 13/50 showed an endothermic peak at 63.7 and 39.9 oC 
respectively. The DSC of SD Batch A, Batch B, Batch C, Batch D 
and Batch E showed an endothermic peak at 64.3, 64.3, 68.4, 63.0 
and 68.6 oC respectively (figure 12-15).  The sharp peaks of the 
drug and the excipients showed crystallinity existence. In the solid 
dispersion formulations, there were two different thermograms 
which was due that the hydrophilic nature of the drug. Batch C and 
E had more broad peak than other batches. The broad peak is an 
indication that the formulations existed in an amorphous state and 
will molecularly entrap more of the drug and which will more create 
pores for drug localization and this will enhance drug release and 
loading efficiency and capacity of drugs. Figure 16 showed the 
combination of all the batches. 
 
 
Figure 8: DSC thermogram of pure metformine 
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Figure 9: DSC thermogram of PEG 4000 
 
 
 
Figure 10: DSC thermogram of Gelucire 13/50 
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Figure 11: DSC thermogram of Batch A (1:1) Solid dispersion formulation 
 
 
 
Figure 12: DSC thermogram of Batch B (1:2) Solid dispersion formulation 
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Figure 13: DSC thermogram of Batch C (2:1) Solid dispersion formulation 
 
 
Figure 14: DSC thermogram of Batch D (1:4) Solid dispersion formulation 
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Figure 15: DSC thermogram of Batch E (4:1) Solid dispersion formulation 
 
 
Figure 16: DSC thermograms of all the excipients of Solid dispersion formulation 
 
Interpretation of FTIR spectrum 
 
When an Infrared (IR) radiation falls on a molecule, it either gets 
absorbed, reflected or transmitted. Absorption leads to the FTIR 
spectrum, while reflection leads to scattering which is utilized in 
Raman Spectroscopy (Clarke et al. 1999). Infrared (IR) absorption 
of the functional groups may vary over a wide range. It has been 
found that many functional groups give characteristics IR absorption 
at specific narrow frequency range [17-19]. The pure metformin 
spectra showed sharp peaks between 1628.62,  3357.15, and 
1067.05 cm-1 signifies the presence of C=N, N-H and C-N functional 
groups respectively in the FTIR spectrum result of the pure 
metformin sample. When compared with the FTIR of the optimum 
batch C, there was no significant change between the spectra of the 
pure drug and the polymers with the formulation. Batch A and B 
solid dispersion by solvent evaporation method had disappearance 
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of sharp peaks unlike in other spectra ratios. This might be an 
indication of an interaction which might be stipulated to be a 
hydrogen bonding between hydrogen atom at N-H and a pair of 
oxygen atom in PEG. Previous reports identified similar type of 
interaction [20-21]. It may also be due to small concentration of 
ratios of the carriers or the method used. Hydrogen bonding has a 
significant influence on the peak shape and intensities, generally 
causing peak broadening and shifts in absorption to lower 
frequencies. The results are shown in Figure 8-20. 
 
 
Figure 8: FTIR spectrum of pure metformin  
 
 
Figure 9: FTIR spectrum of pure PEG 4000 
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Figure 10: FTIR spectrum of pure Gelucire®50/13 
 
 
Figure 11: FTIR spectrum of metformin solid dispersion by solvent evaporation (1:1). 
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Figure 12: FTIR spectrum of metformin solid dispersion by solvent evaporation (1:2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13: FTIR spectrum of metformin solid dispersion by solvent evaporation (2:1). 
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Figure 14: FTIR spectrum of metformin solid dispersion by solvent evaporation (1:4). 
 
 
Figure 15: FTIR spectrum of metformin solid dispersion by solvent evaporation (4:1). 
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Figure 16: FTIR spectrum of metformin solid dispersion by physical mixture (1:1). 
 
 
Figure 17: FTIR spectrum of metformin solid dispersion by physical mixture (1:2). 
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Figure 18: FTIR spectrum of metformin solid dispersion by physical mixture (2:1). 
 
 
Figure 19: FTIR spectrum of metformin solid dispersion by physical mixture (1:4). 
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Figure 20: FTIR spectrum of metformin solid dispersion by physical mixture (4:1). 
 
Conclusion  
 
The solid dispersion technique is a promising alternative for the 
formulation of low permeable drugs such as metformin. The 
encapsulation efficiency (% EE) of Batch C had the highest 
encapsulation efficiency. It was observed that the batch containing 
more PEG 4000 had higher release (Batch C), and after which no 
significant effect was observed when PEG 4000 ratio was further 
increased. This higher percentage release rate of the most 
optimized Batch C will eventually result in an enhanced oral 
bioavailability. 
It was also observed that the release of metformin in SIF was more 
than in SGF medium. 
The FTIR results indicated that absence of any significant change in 
the IR spectral pattern of drug-polymer except with solvent 
evaporation method. 
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